Consensus molecular subtypes (cms) as predictors of benefit from bevacizumab in first line treatment of metastatic colorectal cancer: Retrospective analysis of the MAX clinical trial

Consensus molecular subtypes (cms) as predictors of benefit from bevacizumab in first line treatment of metastatic colorectal cancer: Retrospective analysis of the MAX clinical trial

Saved in:
Bibliographic Details
Published in:Annals of oncology Vol. 28; pp. v160 - v161
Main Authors: Mooi, J., Wirapati, P., Asher, R., Lee, C., Savas, P., Price, T.J., Tejpar, S., Mariadason, J., Tebbutt, N.
Format: Journal Article
Language:English
Published: Elsevier Ltd 01-09-2017
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0923-7534
1569-8041
DOI:10.1093/annonc/mdx393.006